placeUnited Kingdom
Contact & Support
Medtronic / Covidien Products / Therapeutic Endoscopy / Nexpowder™* Endoscopic Hemostasis System

Latest News

Innovations in Endoscopic Hemostatic Powder

ESGE Webinar

Access the Medtronic ESGE webinar and hear from the experts about a new endoscopic hemostasis system for active bleeds and prevention of delayed bleeding after resection.

Watch the webinar

Clinical Education

NexpowderTM* Online Training

Available now

In this online training, you will learn about:

  • NexpowderTM* product and technology 
  • NexpowderTM* clinical efficiency 
  • Indications for NexpowderTM*
  • Product handling
  • Best practice
Register here

NexpowderTM* Nurse Webinar

Taking hemostasis to the next level

Real world experience webinar using NexpowderTM* to solve a variety of gastrointestinal bleeds.

Speakers:

  • Dr Rehan Haidry, Consultant Gastroenterologists, UCLH London
  • MS. Ray-Nina Magcaling, Endoscopy Senior Staff Nurse, UCLH London
Access the free webinar

In-Service Information

 NexpowderTM* Endoscopic Hemostatic System

These instructions provide a step-by-step guide on how to setup and use the NexpowderTM*  Endoscopic Hemostatic System. 

Watch the Instructional Video or download the Procedural Guide.

Download the Procedural Guide

What is Nexpowder™*?

2:41

Clinical Evidence

NexpowderTM* Endoscopic Hemostasis System Clinical Summary

A prospective study assessed the feasibility of Nexpowder™* application in refractory upper gastrointestinal bleeding in 17 patients, and has shown:

  • Successful application in all patients
  • Initial hemostasis in 16 out of 17 patients: 94%.
  • Rebleeding within 30 days was seen in 3 out of 16 patients (19%)
  • Remnants of the gel was evident in 11 out of 16 patients (69%) at the second examination after 24 hours1

In a retrospective study in Korea monotherapy with Nexpowder™* was administered to 56 patients with active bleeding. Immediate hemostasis was achieved in 96.4% (54/56) with a rebleeding rate of 3.7% (2/54) and no adverse events.2

Download the clinical summary

Efficacy of a novel hemostatic adhesive powder in patients with upper gastrointestinal tumor bleeding


Authors: Jongbeom Shin et al. 

Published in: BMC Gastroenterol (2021) 21:40

Conclusion: In conclusion, this single-arm study demonstrated Nexpowder™* was associated with excellent immediate hemostasis rate and safety profile as well as low rebleeding for upper GI tumor bleeding.

Download the clinical summary

Clinical Experience

Nexpowder™* applied in Upper and Lower GI 

In this video, Dr. Beyna discusses his experience with NexpowderTM* in two separate cases, one in the lower GI and one in the upper GI area, and how NexpowderTM* can be applied in both active and non-active bleeding.

Watch now

Nexpowder™* to prevent rebleeding

In this video Dr.  Beyna, demonstrates the assembly of the NexpowderTM* components and using the system on a bleeding site. Upon deployment, NexpowderTM* transforms into a highly adhesive gel that creates a mechanical barrier.

Watch now

Nexpowder™* cases

In this video you can watch an overview of NexpowderTM* being applied in the following cases:

  • Peptic ulcer bleeding
  • Gastric cancer bleeding
  • Post-gastric ESD bleeding
  • Salvage therapy ESD bleeding

Watch now

Would you like to learn more?

Maximum Control. Minimal Clogging.

Hemostatic powder technology that puts you in control.3,4,5

The Nexpowder™* endoscopic hemostasis system is a powder that can be sprayed to an ulcer site, applying an endoscopic hemostatic agent. As a hydrophilic biocompatible adhesive material, it is composed of succinic anhydride (ε-poly-(L-lysine)) and oxidized dextran. 

The Nexpowder™* system forms the adhesive gel after making contact with the water or blood by reversible crosslinking. Crosslinked gel helps prevent bleeding, loss of body fluid and contamination of the ulcer site by adhering to the bleeding site in the gastrointestinal tract and then gel degrades within 1 day to 3 days.3,4,5

Download the product brochure

INTENDED USE

The Nexpowder™* endoscopic hemostasis system is used for most types of GI bleeding. The device is applied during an endoscopic procedure and can cover ulcer or bleeding sites. The device is not intended for use in patients with variceal bleeding.

CONTRAINDICATIONS

Because the Nexpowder™* system includes lactose, it is contraindicated in patients who have galactose intolerance, lapp lactase deficiency, or glucose-galactose malabsorption and they would be at risk of having nausea, bloating, and diarrhoea. Because the Nexpowder™* system includes Brilliant Blue FCF, it must not be used in patients with known hypersensitivity to brilliant blue FCF.

Detect. Resect. Prevent.

How do Medtronic’s gastrointestinal products fit into the patient pathway?

The Detect, Resect, Protect concept follows the patient pathways from detection with the artificial intelligence system GI Genius™, to resection with the ProdiGI™ ESD product portfolio and to bleeding prevention with Nexpowder™*. 

Learn more

Technical Support

A dedicated support center for the solution of technical issues

Customer technical service center for gastrointestinal & hepatology products.

  • Customer Technical Helpline: 01452 223217
  • For more information, email: rs.gi-support@medtronic.com

Detect Early. Treat Early.

Innovating for patients

Early detection and treatment of chronic GI diseases and cancers can be key to better outcomes. Discover how we can support you in achieving proactive GI care for your patients.

Explore our full portfolio of services and solutions

Stay up to date with our latest videos

Check our YouTube channel for more information on our products and services.

Gastrointestinal & Hepatology Videos

Join the discussion

Stay up to date with new products, innovative stories and events.

Medtronic LinkedIn

Interested in learning more?

Contact us to learn more about the clinical applications of Nexpowder™* Endoscopic Hemostasis System.

Nexpowder™* Endoscopic Hemostasis System
Talk with a representative

  • ™* Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company

  • 1. Antunes C, Copelin II EL. Upper Gastrointestinal Bleeding. [Updated 2019 Sep 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470300/

  • 2. Raphaeli T, Menon R. Current treatment of lower gastrointestinal hemorrhage. Clin Colon Rectal Surg. 2012;25(4):219-227. doi:10.1055/s-0032-1329393

  • 3. Park JS, Kim HK, Shin YW, et al. Novel hemostatic adhesive powder for nonvariceal upper gastrointestinal bleeding. Endosc Int Open. 2019 Dec; 7(12):E1763-E1767.

  • 4. Park JS, Bang BW, Hong SJ, et al. Efficacy of a novel hemostatic adhesive powder in patients with refractory upper gastrointestinal bleeding: a pilot study. Endoscopy. 2019 May; 51(5):458-462.

  • 5. Bang B, Lee E, Maeng J, et al. Efficacy of a novel endoscopically deliverable muco-adhesive hemostatic powder in an acute gastric bleeding porcine model. PLoS One. 2019 Jun 11; 14(6):e0216829.

Corporate Resources
Medical Surgical Portfolio
Additional Resources
Contact Us
Medtronic Limited

Building 9, Croxley Park

Hatters Lane

Watford, WD18 8WW

United Kingdom

©2023 Medtronic